Clinch
发表于 2025-3-26 23:16:49
,Peritoneal Metastasis from Small Bowel Adenocarcinoma Associated with Crohn’s Disease,alls. CD most often involves the small intestine and colon. Over the past decades, intestinal adenocarcinoma has been recognized as a complication of CD. The management of patients with peritoneal metastasis (PM) of small bowel adenocarcinoma (SBA) associated with Crohn’s disease (CD) has not been d
ostrish
发表于 2025-3-27 04:01:46
http://reply.papertrans.cn/95/9438/943727/943727_32.png
虚假
发表于 2025-3-27 05:25:08
http://reply.papertrans.cn/95/9438/943727/943727_33.png
啤酒
发表于 2025-3-27 10:10:41
Management of Desmoplastic Small Round Cell Tumor,organ or specific tissue type of origin is unknown. It is rarely isolated to one tumor implant in the abdomen and in most cases presents with dozens to hundreds of abdominal peritoneal tumors. One very large dominant mass is usually present in the omentum with the second and third largest conglomera
过于光泽
发表于 2025-3-27 16:16:24
http://reply.papertrans.cn/95/9438/943727/943727_35.png
ESO
发表于 2025-3-27 21:25:31
The Role of Surgery and Tyrosine Kinase Inhibitors in the Management of Advanced or Recurrent GIST,rointestinal tumors. The annual incidence is 10–13 per 1,000,000, with the majority arising in the stomach (50–60%) and small bowel (20–30%) and only a minority in the large bowel (5%) and esophagus (<5%) . GISTs arise from activating mutations of tyrosine kinase receptors, most commonly by KI
alcohol-abuse
发表于 2025-3-28 00:06:20
Book 2017from different primaries, such as breast cancer, small bowel cancers and imatinib resistant GISTosis and sarcomas and pseudomyxoma. The book provides the most up-to-date information on current approaches such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Given the increasin
修饰语
发表于 2025-3-28 04:42:42
rs.Chapters explore cytoreductive surgery and HIPEC, which a.This book has been designed to provide the full description of the comprehensive management of peritoneal surface malignancies which have originated from different primaries, such as breast cancer, small bowel cancers and imatinib resistan
压迫
发表于 2025-3-28 10:05:31
http://reply.papertrans.cn/95/9438/943727/943727_39.png
Bouquet
发表于 2025-3-28 12:02:14
The Role of Surgery and Tyrosine Kinase Inhibitors in the Management of Advanced or Recurrent GIST,o known mutation in KIT or PDGRF and are wild type. The treatment of GISTs has dramatically changed since 2002 due to the FDA approval of imatinib/Gleevec, a tyrosine kinase inhibitor (TKI) of c-KIT. Imatinib has initial response rates of 75–80% .